First truly end-to-end solution for next-generation sequencing receives Red Dot award
Hilden, Germany, and Germantown, Maryland, April 4, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that the GeneReader NGS System has won a 2016 Red Dot award for excellence in product design. The distinction comes in an international competition among 5,200 entries judged by design experts who evaluate products on criteria such as degree of innovation, functionality, ergonomics and integration with the environment. The GeneReader NGS System is the first complete Sample to Insight next-generation sequencing (NGS) solution designed for any laboratory to deliver actionable insights.
“Earning the Red Dot distinction is very gratifying. We developed our GeneReader NGS workflow in close collaboration with laboratories to meet the need for a simpler, more cost-effective way for clinical testing to take advantage of NGS technology and improve outcomes,” said Jonathan Arnold, QIAGEN’s Oncology Franchise Business Leader. “The novel design comes from working with clinical research labs to create a solution for clinical research labs. Until now, fragmented workflows and bottlenecks have hindered NGS users in this field from achieving actionable insights. The GeneReader NGS System stands out as the world’s first truly end-to-end NGS workflow from primary sample to final report.”
The GeneReader NGS System will be recognized as a winner in the healthcare sub-category of life sciences and medicine at the Red Dot Award: Product Design 2016 ceremony on July 4 in Essen, Germany. All award-winning products including the GeneReader will be presented in a special four-week exhibition, “Design on Stage,” in the Red Dot Design Museum Essen, before entering the museum’s permanent collection. With about 2,000 exhibits from 45 nations, the museum hosts some 150,000 visitors a year. Located in the historic boiler house of the UNESCO World Heritage Site Zollverein coal mine in western Germany, the museum displays the world’s largest exhibition of contemporary design.
Professor Dr. Peter Zec, founder and president of the Red Dot Award organization, said: “With their performances, the Red Dot winners not only demonstrated an extraordinary design quality, but they also showed that design is an integral part of innovative product solutions.”
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2015, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women’s health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
